SISU PHARMA
Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolonged treatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options.
SISU PHARMA
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2019-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.sisupharma.com
Total Employee:
1+
Status:
Active
Total Funding:
3.4 M USD
Similar Organizations
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Stromatis Pharma
Stromatis Pharma is developing a secreted frizzle-related protein 2 (sFRP2) antagonist for reverting stromal stellate cells.
Current Employees Featured
Founder
Investors List
Viva Ventures Biotech Fund
Viva Ventures Biotech Fund investment in Seed Round - Sisu Pharma
Official Site Inspections
http://www.sisupharma.com
- Host name: 47.0.153.160.host.secureserver.net
- IP address: 160.153.0.47
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Sisu Pharma"
SISU PHARMA | EXPLOITING THE STRESS PROTECTION …
Sisu Pharma exploits cellular stress by directly targeting Heat Shock Factor 1 (HSF1), the central regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for …See details»
SISUPHARMA|EXPLOITING THE STRESS PROTECTION …
Sisu Pharma exploits cellular stress by directly targeting Heat Shock Factor 1 (HSF1), the Master Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for …See details»
Sisu Pharma - Crunchbase Company Profile & Funding
Sisu Pharma is developing drugs against a new target to treat prostate cancer. View contacts for Sisu Pharma to access new leads and connect with decision-makers. Sisu Pharma is …See details»
Sisu Pharma - LinkedIn
Sisu Pharma exploits cellular stress by directly targeting HSF1, the Master Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being developed to deliver selective HSF1 ...See details»
About Sean O’Brien - sisupharma
Dr. O’Brien has over 20 years of diverse experience in the drug discovery and development field and has expertise in business development, corporate strategy, and oncology therapeutic …See details»
Sisu Pharma - Company Profile & Staff Directory - ContactOut
Sisu Pharma exploits cellular stress by directly targeting HSF1, the Master Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being developed to deliver selective …See details»
Sisu Pharma, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Jun 20, 2023 Explore Sisu Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Sisu Pharma Company Profile 2024: Valuation, Funding
Sisu Pharma was founded in 2019. Where is Sisu Pharma headquartered? Sisu Pharma is headquartered in San Diego, CA. What is the size of Sisu Pharma? Sisu Pharma has 2 total …See details»
Sisu Pharma - Overview, News & Similar companies - ZoomInfo
View Sisu Pharma (www.sisupharma.com) location in United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Sisu Pharmaceuticals - VentureRadar
Website: https://sisupharma.com/ Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the ...See details»
Sisu Pharma - Products, Competitors, Financials, Employees ...
Sisupharma.com. Overview & Products; Financials; People; Founded Year 2019. Stage Seed VC | Alive. Total Raised $1.7M. Last Raised $1.7M | 4 yrs ago. About Sisu Pharma. Sisu Pharma is …See details»
Sisu Pharma - Viva BioInnovator
Www.sisupharma.com. location. USA, North Carolina, Chapel Hill. modality. Small Molecule. Indications. Oncology. Sisu Pharma is dedicated to developing targeted drugs for patients with …See details»
SISUPHARMA|EXPLOITING THE STRESS PROTECTION RESPONSE
Sisupharma. Pharmaceutical company. CONTACT US. Home; Science; News; CONTACT US. PIPELINE. HSF1 Interacting-Ligand Technology (HI-LiTe) Sisu Pharma has developed its HI …See details»
Sisu (Canada) Company Profile 2024: Valuation, Investors
Sisu (Canada) General Information Description. Manufacturer and marketer of nutritional supplements in British Colombia, Canada. The company's products include supplements for …See details»
Sisu Pharma, Inc. (Sisu Pharma, Inc.) - 药物管线_专利_临床试验_投 …
了解Sisu Pharma, Inc. (Sisu Pharma, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1篇新闻，疾病领域:肿瘤，感染，血液及淋巴系统疾病，神经系统疾病，技术平台:蛋白水解靶向嵌 …See details»
www.sisupharma.com - Viva BioInnovator
Sisu Pharma 是致力于为治疗耐药的前列腺癌患者开发靶向药物。 前列腺癌是全球男性中第二常见的癌症，2018 年全球新发病例超过 130 万。See details»
SISUPHARMA|EXPLOITING THE STRESS PROTECTION RESPONSE
ADDRESS We are located in San Diego, CA and Boston, MA Contact UsPlease include your contact details if you would like a response to yourSee details»
Sisu Pharma Email Format | sisupharma.com Emails
Sisupharma.com; 1 619723XXXX; View Similar People. Related Companies Accelagen. 9 $2m Triton Algae Innovations. 21 $8m Tioga Research. 10 $5.2m Accumetrics. 9 $451m Dermala …See details»
News - sisupharma
Sisu Pharma, a biotech company exploiting cellular stress to treat therapy-resistant cancers, is delighted to announce that Professor Michael Jung has joined its Scientific Advisory Board.See details»
Sisu Pharma Welcomes Renowned Prostate Cancer Drug …
Apr 20, 2023 Sisu Pharma (www.sisupharma.com) is a biotechnology company focused on exploiting cellular stress by directly targeting the previously undruggable transcription factor …See details»